Summary
Pfizer Inc. is undergoing a significant strategic transformation, as evidenced by the recent IPO of its Animal Health business, Zoetis. This move, along with the divestiture of its Nutrition business to Nestlé and the sale of Capsugel, signals a clear focus on its core biopharmaceutical operations. The company is emphasizing its innovative core (Primary Care, Specialty Care, and Oncology) and its value core (Established Products), alongside a global Emerging Markets unit. Despite these strategic shifts, Pfizer faces considerable challenges, including patent expirations for key products like Lipitor and the increasing threat of generic competition. The company's R&D spending remains substantial, reflecting a commitment to innovation, but also highlighting the inherent risks and unpredictability of drug development. Investors should monitor the success of pipeline products and the company's ability to navigate the complex regulatory and pricing environments in both developed and emerging markets.
Financial Highlights
56 data points| Revenue | $54.66B |
| Cost of Revenue | $9.82B |
| Gross Profit | $44.84B |
| SG&A Expenses | $15.17B |
| Operating Income | $8.99B |
| Interest Expense | $1.52B |
| Net Income | $14.57B |
| EPS (Basic) | $1.96 |
| EPS (Diluted) | $1.94 |
| Shares Outstanding (Basic) | 7.44B |
| Shares Outstanding (Diluted) | 7.51B |
Key Highlights
- 1Pfizer completed the IPO of its Animal Health subsidiary, Zoetis, in February 2013, marking a strategic shift towards its core biopharmaceutical business.
- 2The company divested its Nutrition business to Nestlé for $11.85 billion in cash in November 2012, further streamlining its portfolio.
- 3Biopharmaceutical revenues, while still dominant at 87% of total revenues in 2012, saw a 11% decrease compared to 2011, primarily due to loss of exclusivity for key products like Lipitor.
- 4Significant R&D investment of $7.9 billion in 2012 underscores Pfizer's commitment to innovation, with 78 programs in Phase 1 through registration.
- 5The company is strategically realigning its R&D focus to five high-priority areas: immunology and inflammation; oncology; cardiovascular and metabolic diseases; neuroscience and pain; and vaccines.
- 6International operations represent a substantial portion of revenue, accounting for 61% in 2012, though these markets present unique regulatory and pricing challenges.
- 7Pfizer is actively repurchasing shares, with approximately $135.98 million worth of shares purchased under announced plans in the fourth quarter of 2012.